Midatech Pharma US partners with R-Pharm US to co-promote Zuplenz and Oravig

Under the terms of the agreement, R-Pharm will promote Zuplenz and Oravig in accounts that are not currently in the Midatech Pharma US call universe as well as provide additional promotion in accounts where Midatech currently markets its oncology supportive care product portfolio.

Midatech Pharma US president David Benharris said: “We are extremely excited to add a valued partner in R-Pharm, who can provide additional promotional reach into new accounts as well as supplemental frequency to additional call points in our targeted offices.

"Our products, as with many pharmaceuticals products, are detail sensitive. The partnership with R-Pharm provides an enriched share of voice to further bolster our ongoing commercial efforts for both Zuplenz and Oravig.”

R-Pharm US president and CEO Mark Pavoa said: “Zuplenz and Oravig are complementary to our oncology franchise, which includes Ixempra. Cancer patients and treatment teams face many challenges as they battle the disease, and we are proud to represent these two additional potential solutions.”

Demetrios Kydonieus, President and Chief Business Officer of R-Pharm US, commented: “Adding Zuplenz and Oravig to our existing portfolio allows us to leverage our commercialisation investment and to increase the value we bring to patients and the medical offices we serve.”

Zuplenz is the only oral soluble film formulation of the 5-HT3 receptor antagonist ondansetron, indicated for the prevention of nausea and vomiting associated with the use of highly and moderately emetogenic cancer chemotherapies, radiotherapy, and in postoperative patients.

Oravig is the only once-daily local therapy available for treatment of oral thrush in adults. All other currently marketed, localised therapies for oral thrush require patients to take/administer their treatment a minimum of four times daily.

R-Pharm will begin promoting both Oravig and Zuplenz in January of 2017.